Tianci International

Tianci International
Shanghai tianci international pharmaceutical co., LTD
Shanghai Tianci International Pharmaceuticals Co., Ltd. (hereinafter referred to as "Tianci") is a comprehensive biopharmaceutical enterprise integrating R&D, production and sales. After 13 years of development, Tianci has won the honors of High-tech Enterprises, Shanghai Science and Technology Small Giant Enterprise and Headquarters with Rapid Growth in Pudong New Area. Tianci has undertaken a number of major national and provincial science and technology projects, and has made major breakthroughs in cancer, cardiovascular and nervous system research.

Headquartered in Zhangjiang, Shanghai and covering 211 mu of industrial land in Zhangjiang Hi-Tech Park, Tianci is developing the Base for Transformation of Tianci International Biomedical Achievements with a total floor area of 280,000 square meters, of which production facilities meet international first-class technical standards and up to 80 GMP production lines can be provided. As Zhangjiang is known as "China’s Medicine Valley", this base will strongly support Zhangjiang's biomedical innovation chain as a functional platform for the transformation of Zhangjiang's biomedical achievements. This project has been recognized as a strategic emerging major industrial project and a key technological transformation project in Shanghai.

  • 211
    industrial land
  • 28
    Biomedical Achievements
  • 80
    GMP production lines
  • 13
    After 13 years of development

It is well-known in the industry that it is difficult to transform biomedical achievements. Tianci International adopts the "A + W" innovative industrial model to address “the last mile” of industrialization, in which "A" refers to the centralized production of a batch of innovative drugs and high-end generic drugs accumulated by Tianci International through independent innovation; and "W" stands for "We Pharma", meaning that we all produce medicine together. "We Pharma" is an innovative mode of developing new drugs based on equity cooperation created by MAH system, so as to maximize the division of labor and cooperation between scientists and enterprises, as well as safeguard scientists’ practical interests at maximum. Tianci takes its own R&D technology as the core foundation, integrates R&D, production and sales of biomedicine into a whole industry chain platform. It is a "flexible, open and giving" sharing platform for the whole industry chain, which enables more scientists from all over the world to "produce medicine together" in Shanghai and allows people to afford highly-efficient and secure medicine.